Optrex ActiMist has partnered with EYELogic to provide a direct wholesale distribution stream to the Australian optical market.
Since being launched by Reckitt Benckiser (RB) in Australia in the second quarter of 2013, Optrex ActiMist has gained solid market share in both pharmacy and grocery channels, and is now number two position in the eye care category, according to the company.1
Optrex ActiMist is a liposomal spray that is clinically proven to help repair the lipid layer of the tear film and seal the moisture into the eye.2 According to Reckitt Benckiser the product overcomes many of the pitfalls patients experience using eye drops as it’s sprayed onto a closed eye.
Approximately 80 per cent of sore, irritated eyes are due to damage to the lipid layer3 often caused by environmental factors such as weather, computer use and air conditioning. Optrex ActiMist is promoted as providing a convenient, easy way to treat this discomfort.
RB is thrilled to be partnering with EYELogic
“RB is thrilled to be partnering with EYELogic for the distribution of Optrex ActiMist to optometrists nationally,” said Vanessa McCutcheon, Professional Relations and Marketing Manager at Reckitt Benckiser.
“We have experienced overwhelming response from optometrists interested in stocking the Optrex range and we will work with EYELogic to place these orders as efficiently as possible.”
The EYELogic Company was founded by owners with more than 30 years of combined experience in the Australian optical industry and launched in May 2014, with the aim of providing quality industry-specific and eye-health related consumables to the optical retail market.
Optometry practices can place orders for Optrex ActiMist products using the self-service online portal at www.eyelogic.com.au or by calling the customer service team on (AUS) 02 9371 8884. For more Optrex product information, visit rbhealthhub.com.au
1. Nielsen Combined Eye Care LQTR 06.04.14
2. Pult H et al. Contact Lens Anterior Eye 2012;35(35): 203-207;
3. Dausch D et al. Klin Monatsbl Augenheilkd 2006: 223: 974-983